[Retracted] Clinical significance of bromodomain-containing protein 7 and its association with tumor progression in prostate cancer. [PDF]
Liang Y, Dong B, Shen J, Ma C, Ma Z.
europepmc +1 more source
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source
Integrated transcriptomic analysis reveals a CEBPB-DUSP1 axis driving tumor progression in colorectal cancer. [PDF]
Zhou H, Fang L.
europepmc +1 more source
Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung +17 more
wiley +1 more source
Decoding SDCBP's role in tumor progression and immune cells infiltration: from databases to macrophage validation. [PDF]
Zhao C +12 more
europepmc +1 more source
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon +9 more
wiley +1 more source
Methylmalonic acid modulates neutrophil function to promote tumor progression in colorectal cancer. [PDF]
Hu F +9 more
europepmc +1 more source
Understanding the tumor immune microenvironment (TIME) for effective therapy
M. Binnewies +18 more
semanticscholar +1 more source
Redox regulation meets metabolism: targeting PRDX2 to prevent hepatocellular carcinoma
PRDX2 acts as a central redox hub linking metabolic dysfunction‐associated steatohepatitis (MASH) to hepatocellular carcinoma (HCC). In normal hepatocytes, PRDX2 maintains redox balance and metabolic homeostasis under oxidative stress. In contrast, during malignant transformation, PRDX2 promotes oncogenic signaling, stemness, and tumor initiation ...
Naroa Goikoetxea‐Usandizaga +2 more
wiley +1 more source
Editorial: Ferroptosis and regulation mechanism in the tumor immune microenvironment for tumor progression and treatment. [PDF]
Wei Y, Pan J, Wang L, Pan Y.
europepmc +1 more source

